Τίτλος:
Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review)
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The major impact produced by the severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) focused many researchers attention to find treatments that can suppress transmission or ameliorate the disease. Despite the very fast and large flow of scientific data on possible treatment solutions, none have yet demonstrated unequivocal clinical utility against coronavirus disease 2019 (COVID-19). This work represents an exhaustive and critical review of all available data on potential treatments for COVId-19, highlighting their mechanistic characteristics and the strategy development rationale. Drug repurposing, also known as drug repositioning, and target based methods are the most used strategies to advance therapeutic solutions into clinical practice. current in silico, in vitro and in vivo evidence regarding proposed treatments are summarized providing strong support for future research efforts. © 2020 Spandidos Publications. All rights reserved.
Συγγραφείς:
Nitulescu, G.M.
Paunescu, H.
Moschos, S.A.
Petrakis, D.
Nitulescu, G.
Ion, G.N.D.
Spandidos, D.A.
Nikolouzakis, T.K.
Drakoulis, N.
Tsatsakis, A.
Περιοδικό:
International Journal of Molecular Medicine
Εκδότης:
Spandidos Publications
Λέξεις-κλειδιά:
8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one; amprenavir; angiotensin converting enzyme 2; aprotinin; atazanavir; baricitinib; bromhexine; chloroquine; darunavir; diminazene aceturate; favipiravir; galidesivir; hydroxychloroquine; immunoglobulin A; immunoglobulin G; immunoglobulin M; indinavir; interleukin 10; interleukin 6; lopinavir plus ritonavir; nafamstat; nelfinavir; niclosamide; remdesivir; ribavirin; ritonavir; ruxolitinib; saquinavir; tipranavir; unindexed drug; angiotensin 1 receptor; angiotensin 1 receptor antagonist; angiotensin converting enzyme 2; bromhexine; camostat; chlorpromazine; diminazene; dipeptidyl carboxypeptidase; gabexate; recombinant protein, antiviral activity; coronavirus disease 2019; diarrhea; drug approval; drug repositioning; gene mutation; genetic variability; human; innate immunity; nausea; nonhuman; pathogenesis; priority journal; protein expression; protein processing; QT prolongation; Review; single nucleotide polymorphism; treatment outcome; treatment planning; treatment response; viral clearance; virus cell interaction; virus genome; virus morphology; virus replication; virus virulence; vomiting; Betacoronavirus; chemistry; classification; clinical trial (topic); coronavirus disease 2019; Coronavirus infection; drug effect; drug repositioning; metabolism; mortality; pandemic; pathogenicity; physiology; procedures; signal transduction; virus entry; virus pneumonia, Angiotensin II Type 1 Receptor Blockers; Betacoronavirus; Bromhexine; Chlorpromazine; Clinical Trials as Topic; Coronavirus Infections; Diminazene; Drug Repositioning; Gabexate; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Receptor, Angiotensin, Type 1; Recombinant Proteins; Signal Transduction; Virus Internalization
DOI:
10.3892/ijmm.2020.4608
